US-Based Carlyle Buys 20% Stake In Piramal Pharma Businesses

US-Based Carlyle Buys 20% Stake In Piramal Pharma Businesses

[ad_1]

Mumbai-based conglomerate Piramal Enterprises said on Saturday that US-based investment firm Carlyle Group will purchase a 20 per cent stake in its pharmaceutical unit for around $490 million (Rs 3,706.36 crore at Rs 1 = $75.64). Piramal Enterprises will integrate its pharmaceuticals businesses into its wholly-owned subsidiary Piramal Pharma, which will use the capital raised through the deal to accelerate its organic and inorganic growth plans. In a regulatory filing early on Saturday, Piramal Enterprises said the deal values its pharma business at an enterprise value of $2,775 million, with an upside component of up to $360 million depending on the company’s performance in the current financial year.

Piramal Enterprises said the transaction, expected to close in 2020 and subject to regulatory cearance, is one of the largest private equity deals in the country’s pharmaceutical sector.

The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal. 

[ad_2]

Source link

Rate this post

leave your comment


Your email address will not be published. Required fields are marked *